Scribe Therapeutics Inc.
SCTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$342.57M
Close$
Share Statistics
| Market cap | $342.57 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | 0 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-3.62
Average shareholder expectationRevenue Estimate
$3.11 M
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$3.72 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Scribe Therapeutics Inc.
89 employees
CEO: Benjamin L. Oakes Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on...